14-3-3 sigma and p53 expression in gastric cancer and its clinical applications

Disease Markers

Volumn 29, Issue 1, 2010, Pages 21-29

  Mühlmann, Gilbert ^a   Öfner, Dietmar ^b   Zitt, Matthias ^a   Müller, Hannes M ^a   Maier, Hans ^a   Moser, Patrizia ^a   Schmid, Kurt W ^c   Zitt, Marion ^a   Amberger, Albert ^d  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

14 3 3 sigma; Gastric cancer; tumorigenesis

Indexed keywords

PROTEIN P53; STRATIFIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; STOMACH CANCER;

EID: 77957237324     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/470314     Document Type: Article

References (29)

1. T.A. Chan, H. Hermeking, C. Lengauer, K.W. Kinzler and B. Vogelstein, 1433Sigma is required to prevent mitotic catastrophe after DNA damage, Nature 401(6753) (7 Oct 1999), 616-620. (Pubitemid 129517080)
2. H. Fu, R.R. Subramanian and S.C. Masters, 1433 proteins: structure, function, and regulation, Annu Rev Pharmacol Toxicol 40 (2000), 617-647.
3. E.W. Wilker, M.A. van Vugt, S.A. Artim et al., 1433sigma controls mitotic translation to facilitate cytokinesis, Nature 446(7133) (15 Mar 2007), 329-332.
4. H. Hermeking, C. Lengauer, K. Polyak et al., 1433 sigma is a p53regulated inhibitor of G2/M progression, Mol Cell 1(1) (Dec 1997), 3-11. (Pubitemid 127376388)
5. H.Y. Yang, Y.Y. Wen, C.H. Chen, G. Lozano and M.H. Lee, 1433 sigma positively regulates p53 and suppresses tumor growth, Mol Cell Biol 23(20) (Oct 2003), 7096-7107. (Pubitemid 37210993)
6. C.B.Umbricht, E. Evron, E.Gabrielson, A. Ferguson, J.Marks and S. Sukumar, Hypermethylation of 1433 sigma (stratifin) is an early event in breast cancer, Oncogene 20(26) (7 Jun 2001), 3348-3353. (Pubitemid 32588983)
7. M. Gasco, A. Sullivan, C. Repellin et al., Coincident inactivation of 1433sigma and p16INK4a is an early event in vulval squamous neoplasia, Oncogene 21(12) (14 Mar 2002), 1876-1881. (Pubitemid 34259190)
8. A.S. VercoutterEdouart, J. Lemoine, X. Le Bourhis et al., Proteomic analysis reveals that 1433sigma is downregulated in human breast cancer cells, Cancer Res 61(1) (1 Jan 2001), 76-80. (Pubitemid 32095703)
9. T. Urano, T. Saito, T. Tsukui et al., Efp targets 1433 sigma for proteolysis and promotes breast tumour growth, Nature 417(6891) (20 Jun 2002), 871-875. (Pubitemid 34670336)
10. N. Iwata, H. Yamamoto, S. Sasaki et al., Frequent hypermethylation of CpG islands and loss of expression of the 1433 sigma gene in human hepatocellular carcinoma, Oncogene 19(46) (2 Nov 2000), 5298-5302
11. H. Suzuki, F. Itoh, M. Toyota, T. Kikuchi, H. Kakiuchi and K. Imai, Inactivation of the 1433 sigma gene is associated with 5' CpG island hypermethylation in human cancers, Cancer Res 60(16) (15 Aug 2000), 4353-4357. (Pubitemid 32103610)
12. M. Kaneuchi, M. Sasaki, Y. Tanaka et al., Expression and methylation status of 1433 sigma gene can characterize the different histological features of ovarian cancer, Biochem Biophys Res Commun 316(4) (16 Apr 2004), 1156-1162. (Pubitemid 38369074)
13. H. Osada, Y. Tatematsu, Y. Yatabe et al., Frequent and histological typespecific inactivation of 1433sigma in human lung cancers, Oncogene 21(15) (4 Apr 2002), 2418-2424. (Pubitemid 34407301)
14. L. Cheng, C.X. Pan, J.T. Zhang et al., Loss of 1433sigma in prostate cancer and its precursors, Clin Cancer Res 10(9) (1 May 2004), 3064-3068. (Pubitemid 38619684)
15. M.Gasco, A.K. Bell, V. Heath et al., Epigenetic inactivation of 1433 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity, Cancer Res 62(7) (1 Apr 2002), 2072-2076. (Pubitemid 34408454)
16. M. Ide, T. Nakajima, T. Asao and H. Kuwano, Inactivation of 1433sigma by hypermethylation is a rare event in colorectal cancers and its expression may correlate with cell cycle maintenance at the invasion front, Cancer Lett 207(2) (30 Apr 2004), 241-249. (Pubitemid 38457046)
17. C.H. Wittekind, TNM Atlas: Illustrated Guide to the TNM Classification of Malignant Tumours (UICC). WileyBlackwell. ISBN: 9780471743019.
18. WHO Classification of Tumors. Pathology and Genetics of Tumors of Digestive System. IARC Press 2000.
19. J.S. Macdonald, S.R. Smalley, J. Benedetti et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med 345 (2001), 725-730.
20. A. Perathoner, D. Pirkebner, G. Brandacher et al., 1433sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients, Clin Cancer Res 11(9) (1 May 2005), 3274-3279. (Pubitemid 40627875)
21. H. Hermeking, 1433 proteins and cancer biology, Semin Cancer Biol 16(3) (Jun 2006), 161.
22. T. Samuel, H.O. Weber, P. Rauch, B. Verdoodt, J.T. Eppel, A. McShea et al., The G2/M regulator 1433sigma prevents apoptosis through sequestration of Bax, J Biol Chem 276 (2001), 45201-45206. (Pubitemid 37391314)
23. Y. Zhang,M.Karas, H. ZhaoH, S.Yakar andD. LeRoith, 1433sigmamediation of cell cycle progression is p53independent in response to insulinlike growth factorI receptor activation, J Biol Chem 279 (2004), 34353-34360. (Pubitemid 39318060)
24. K. Tanaka, T. Hatada, M. Kobayashi et al., The clinical implication of 1433 sigma expression in primary gastrointestinal malignancy, Int J Oncol 25(6) (Dec 2004), 1591-1597.
25. K. Laimer, N. Blassnig, G. Spizzo et al., Prognostic significance of 1433sigma expression in oral squamous cell carcinoma (OSCC), Oral Oncol 45(2) (Feb 2009), 127-134.
26. N.K. Yoon, D.B. Seligson, D. Chia et al., Higher expression levels of 1433sigma in ductal carcinoma in situ of the breast predict poorer outcome, Cancer Biomark 5(4) (2009), 215-224
27. J.M. Nigro, S.J. Baker, A.C. Preisinger et al., Mutations in the p53 gene occur in diverse human tumour types, Nature 342(6250) (7 Dec 1989), 705-708.
28. H.H. Ishii, G.C. Gobe and Y. Ebihara, p53 is an indicator of tumor progression in early but not advanced gastric carcinomas, Hepatogastroenterology 54(79) (OctNov 2007), 2159-2163.
29. U. Drebber, S.E. Baldus, B. Nolden et al., The overexpression of cmet as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation, Oncol Rep 19(6) (Jun 2008), 1477-1483.